Copyright
©The Author(s) 2021.
World J Gastroenterol. Aug 28, 2021; 27(32): 5424-5437
Published online Aug 28, 2021. doi: 10.3748/wjg.v27.i32.5424
Published online Aug 28, 2021. doi: 10.3748/wjg.v27.i32.5424
Table 5 Reasons for permanent sorafenib discontinuation, n (%)
| Group A (n = 41) | Group B (n = 30) | Group C (n = 63) | Group A vs Group B, P value | Group A vs Group C, P value | Group B vs Group C, P value | |
| Progression | 26 (63.4) | 7 (23.3) | 33 (52.4) | 0.006 | 1.000 | 0.046 |
| Intolerance | 7 (17.1) | 18 (60.0) | 13 (20.6) | 0.002 | 1.000 | 0.001 |
| Liver failure | 6 (14.6) | 3 (10.0) | 8 (12.7) | 1.000 | 1.000 | 1.000 |
| Other | 2 (4.9) | 2 (6.7) | 9 (14.3) | 1.000 | 0.690 | 1.000 |
- Citation: Ochi M, Kamoshida T, Araki M, Ikegami T. Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment. World J Gastroenterol 2021; 27(32): 5424-5437
- URL: https://www.wjgnet.com/1007-9327/full/v27/i32/5424.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i32.5424